Treace Medical Concepts, Inc. revised revenue guidance for the full year 2022. For the year, the company revenue is anticipated to be in the range of $141.2 to $141.7 million, representing an increase of 50% over the same periods last year. For the full year 2022, the company previously provided revenue guidance to be in the range of $135 million to $138 million, which represented approximately 43% to 46% growth over the Company's 2021 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.45 USD | +2.80% |
|
+25.19% | -33.73% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.73% | 524M | |
+75.69% | 12.57B | |
-21.78% | 7.63B | |
-6.25% | 5.84B | |
+8.16% | 5.16B | |
-17.50% | 4.75B | |
+16.22% | 4.16B | |
-12.24% | 4.17B | |
-10.69% | 3.37B | |
-1.24% | 1.99B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Full Year 2022